Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified vs Standard XELOX plus Sintilimab in HER2-negative Gastric Cancer
NCT05918094Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University. Started Apr 2023; status: recruiting.
02
Drugs
sintilimabcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05918094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918094.